Castle Biosciences, Inc.
NASDAQ:CSTLMedical - Diagnostics & Research
+$0.04 today
- Market cap
- $1.03B
- Beta
- 1.02
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.43
Volume 0.38M
Average 0.37M
CSTL Total Debt
Short-term and long-term borrowings combined.
Castle Biosciences, Inc.NASDAQ: CSTL
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 42.1% from a year ago
Total debt stood at $36.72M at the end of Q1 FY2026, up 42.1% from a year earlier and down 0.5% from the prior quarter. Over 3 fiscal years it compounded at +40.2% a year.
Context
- Total debt amounted to 6.7% of total assets at the end of Q1 FY2026, up 1.6 pp from a year earlier.
- Total debt increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +42.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 36.91M USD
- Year-over-year change
- +40.1%
- 4-year CAGR
- +45.6%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.91M | +40.1% |
| FY2024 | 2024-12-31 | 26.34M | +71.8% |
| FY2023 | 2023-12-31 | 15.34M | +14.4% |
| FY2022 | 2022-12-31 | 13.4M | +63.4% |
| FY2021 | 2021-12-31 | 8.2M | — |
Total Debt vs competitors
How CSTL compares with its peers on the latest reported figures
- CSTL's Mar 2026 total debt of $36.72M is the lowest of the 8 companies compared; the peer median is $105.85M.
- Its year-over-year change of +42.1% is the highest of 8, against a peer median of +15.0%.
- Total debt amounts to 6.7% of total assets for CSTL, versus a peer median of 33.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.69B | +27.5% | +7.7% | 89.7% | |
| Jun 2026 | $448.37M | +8.9% | -8.2% | 33.2% | |
| Mar 2026 | $211.5M | +34.2% | +13.1% | 31.4% | |
| Jun 2026 | $105.85M | +26.0% | +33.7% | 80.1% | |
| Mar 2026 | $71.61M | +15.0% | +31.8% | 75.7% | |
| Jun 2026 | $40.11M | -20.8% | +39.1% | 2.7% | |
| Mar 2026 | $38.78M | -12.7% | -6.4% | 11.9% | |
| Mar 2026 | $36.72M | +42.1% | +40.2% | 6.7% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding CSTL) | $105.85M | +15.0% | +13.1% | 33.2% | |
Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 329.63M | 122.95M | 98.84M | 119.71M | 116.73M |
| Short-term Investments | 0 | 135.68M | 144.26M | 173.42M | 182.78M |
| Net Receivables | 17.28M | 23.48M | 38.3M | 51.22M | 43.38M |
| Inventory | 2.02M | 3.98M | 7.94M | 8.14M | 10.25M |
| Other Current Assets | 4.81M | 6.21M | 6.29M | 7.67M | 7.96M |
| Total Current Assets | 353.74M | 292.29M | 295.64M | 360.15M | 361.1M |
| Property, Plant & Equipment (Net) | 16.88M | 26.5M | 37.74M | 62.71M | 112.24M |
| Goodwill | 0 | 10.69M | 10.69M | 10.69M | 10.69M |
| Intangible Assets | 88.92M | 115.66M | 106.64M | 95.54M | 88.88M |
| Long-term Investments | 1.31M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.72M | 2.2M | 2.63M | 2.15M | 5.65M |
| Total Non-current Assets | 108.83M | 155.04M | 157.71M | 171.08M | 217.46M |
| Total Assets | 462.57M | 447.33M | 453.34M | 531.24M | 578.56M |
| Account Payables | 2.55M | 4.73M | 10.27M | 6.9M | 18.71M |
| Short-term Debt | 0 | 0 | 0 | 278K | 417K |
| Tax Payables | 695K | 37K | 0 | 1.08M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 16.91M | 25.67M | 30.69M | 774K | 42.34M |
| Total Current Liabilities | 24.89M | 36.13M | 47.67M | 49.39M | 68.68M |
| Long-term Debt | 0 | 0 | 0 | 9.75M | 9.64M |
| Deferred Tax Liabilities | 635K | 428K | 206K | 1.61M | 2.34M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 18.29M | 0 | 0 | 0 | 1.5M |
| Total Non-current Liabilities | 25.95M | 12.05M | 14.4M | 26.01M | 39.01M |
| Total Liabilities | 50.83M | 48.18M | 62.07M | 75.4M | 107.68M |
| Common Stock | 25K | 27K | 27K | 28K | 30K |
| Retained Earnings | (93.77M) | (160.91M) | (218.37M) | (200.13M) | (224.28M) |
| Accumulated OCI | 0 | (381K) | 136K | 230K | 267K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 411.74M | 399.15M | 391.27M | 455.84M | 470.87M |
| Total Debt | 8.2M | 13.4M | 15.34M | 26.34M | 36.91M |
| Net Debt | (321.43M) | (109.55M) | (83.51M) | (93.37M) | (79.82M) |
Castle Biosciences, Inc.
NASDAQ:CSTL
Intrinsic Alpha fair value
Locked
Current Price
$33.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.